Current Coverage Status
Not Yet FDA-Approved
CT-388 is currently in Phase 2 clinical trials and is not available by prescription. Insurance coverage is not applicable until after FDA approval, which is projected for 2029-2030.
Until FDA approval, the only way to access CT-388 is through clinical trial participation in the Phase 2 program (NCT06525935, NCT06628362).
Post-Approval Coverage Outlook
When CT-388 is eventually FDA-approved (estimated 2029-2030), coverage will depend on several factors unique to Roche's position:
Roche's Commercial Advantages
- Global pharma presence: Roche is one of the world's largest pharmaceutical companies with established payer relationships
- Commercial infrastructure: Unlike small biotechs, Roche has existing salesforce, medical affairs, and market access teams
- Reimbursement expertise: Track record of securing coverage for specialty medications
- Financial resources: Ability to invest in patient assistance and co-pay programs
- Pipeline breadth: Multiple obesity assets allow portfolio-level negotiations
Coverage Challenges
- Late market entry: CT-388 will enter a market with established competitors (Zepbound, Wegovy, potentially CagriSema, retatrutide). Payers may require step therapy through existing options first.
- Obesity medication exclusions: Many insurance plans still exclude or heavily restrict obesity medications.
- Medicare Part D: By law, basic Part D coverage excludes drugs used for weight loss, unless the drug is also approved for another use (like diabetes). CT-388 is not a Medicare GLP-1 Bridge drug.
- Cost pressures: Payers increasingly scrutinizing high-cost GLP-1 medications.
Potential Coverage Advantages
- Signal-biased mechanism: If Phase 3 shows clinical advantages (sustained efficacy, improved tolerability), this could support differentiated formulary placement
- Type 2 diabetes indication: If approved for T2D (Phase 2 ongoing), Medicare Part D coverage becomes possible
- Combination therapy: CT-388 + Petrelintide combination could offer unique value proposition
- Competition benefits: More market options could drive better terms across the category
Expected Pricing
No pricing has been announced for CT-388. Based on the competitive landscape:[1]
| Drug | List Price | Notes |
|---|---|---|
| Wegovy (semaglutide) | ~$1,349/month | Established GLP-1 for obesity |
| Zepbound (tirzepatide) | ~$1,060/month | Dual GLP-1/GIP agonist |
| CT-388 (projected) | $1,000-1,300/month | Analyst estimates |
Pricing strategy considerations:
- Competitive pricing: Roche may price at or below Zepbound to gain market share
- Value-based pricing: If CT-388 shows superior efficacy, premium pricing possible
- Peak sales target: Roche projects >$3B peak sales, suggesting volume strategy
Future Access Strategies
Current Access (Pre-Approval)
- Clinical trials: Phase 2 trials currently enrolling (NCT06525935, NCT06628362)
- No commercial access: CT-388 cannot be purchased or prescribed
- No compounding: CT-388 is not available through compounding pharmacies
Post-Approval Access (2030+)
- Patient assistance programs: Roche will likely offer comprehensive co-pay assistance and income-based programs
- Prior authorization: Expect to need documentation of obesity, failed diet/exercise, and potentially failed other medications
- Appeals process: If initially denied, work with your physician to document medical necessity and appeal
- Employer plans: Some employer plans offer better obesity medication coverage than individual plans
Roche's Patient Support Advantage
Roche has extensive experience with patient assistance programs through drugs like Ocrevus, Hemlibra, and cancer medications. Patients can expect robust support infrastructure when CT-388 launches.
FAQs
Coverage is uncertain and won't be determined until after FDA approval (projected 2029-2030). Based on current obesity medication coverage patterns:
- Many commercial plans exclude or restrict obesity medications
- Step therapy through existing drugs may be required
- By law, basic Medicare Part D coverage excludes drugs used for weight loss (unless also approved for another use, such as diabetes)
Roche's commercial strength may help secure better coverage than smaller competitors.
No pricing is available yet. Analysts estimate CT-388 could cost $1,000-1,300/month based on comparable drugs:
- Zepbound: ~$1,060/month
- Wegovy: ~$1,349/month
Roche will likely offer patient assistance programs to reduce costs for eligible patients.
By law, basic Medicare Part D coverage excludes drugs used for weight loss, and CT-388 is not a Medicare GLP-1 Bridge drug. However:
- T2D indication: If CT-388 is approved for type 2 diabetes (Phase 2 ongoing), Medicare coverage for that indication becomes possible
- Legislation: The Treat and Reduce Obesity Act, if passed, could expand Medicare coverage—but passage is not guaranteed
CT-388 will be a late market entrant competing against established products. Roche's strategy includes:
- Efficacy differentiation: If signal-biased mechanism shows advantages
- Combination therapy: CT-388 + Petrelintide may offer unique benefits
- Portfolio approach: Multiple assets (CT-388, CT-996 oral, combinations)
- Payer relationships: Leverage existing Roche formulary positions
Roche is targeting becoming a "top 3" player in the obesity market.
Sources & References
- GoodRx. GLP-1 Pricing Data. 2025. https://www.goodrx.com
- Kaiser Family Foundation. "Medicare and Obesity Medications." 2024. https://www.kff.org
- FierceBiotech. "Roche unveils strategy to become 'top 3' obesity company." September 2025. https://www.fiercebiotech.com/biotech/we-have-will-roche-unveils-strategy-become-top-3-obesity-company
- Roche Pharma Day 2025 Presentation. September 22, 2025. https://assets.roche.com/f/176343/x/059c686d27/20250922_pharma-day-2025_vf_online.pdf
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.